In a study, the effect of prilocaine on pre- and postnatal development was examined in rats treated with up to 2.8 times the maximum recommended human dose of prilocaine in lidocaine-prilocaine gel from day 6 of gestation to weaning. There was no evidence of altered postnatal development, viability, or reproductive capacity in any offspring.

Lidocaine-prilocaine topical cream has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of impaired fertility or fetal harm. There are no controlled data in human pregnancy. Lidocaine-prilocaine topical cream is only recommended for use during pregnancy when benefit outweighs risk.

See references

Lidocaine, and probably prilocaine, are excreted into human milk. Following application of the cream to a nursing mother, the milk:plasma ratio of lidocaine is 0.4 and is not determined for prilocaine. The manufacturer recommends that caution be used when administering lidocaine-prilocaine topical cream to nursing women.

See references